Home
HelpTest ID: CA153 Cancer Antigen 15-3 (CA 15-3), Serum
Reporting Name
Cancer Ag 15-3, (CA 15-3), SUseful For
Managing breast cancer patients when used in conjunction with clinical information and other diagnostic procedures
Serial testing to assist in early detection of disease recurrence in previously treated stage II and III breast cancer patients
Monitoring response to therapy in metastatic breast cancer patients
This test is not useful as a cancer screening test.
Clinical Information
Carcinoma of the breast is the most prevalent form of cancer in women. These tumors often produce mucinous antigens, which are large molecular weight glycoproteins with O-linked oligosaccharide chains. Tumor-associated antigens encoded by the human MUC-1 gene are known by several names, including MAM6, milk mucin antigen, cancer antigen (CA) 27.29, and CA 15-3.
CA 15-3 assay values are not elevated in most normal individuals and are frequently elevated in sera from breast cancer patients.
Nonmammary malignancies in which elevated CA 15-3 assay values have been reported include: lung, colon, pancreas, primary liver, ovary, cervix, and endometrium.
Interpretation
Increasing and decreasing values show correlation with disease progression and regression, respectively.(1) Increasing cancer antigen 15-3 (CA 15-3) assay values in patients at risk for breast cancer recurrence after primary therapy may be indicative of recurrent disease before it can be detected clinically (2,3) and may be used as an indication that additional tests or procedures should be performed.
Report Available
1 to 3 daysDay(s) Performed
Monday through Saturday
Clinical Reference
1. Molina R, Zanon G, Filella X, et al. Use of serial carcinoembryonic antigen and CA 15-3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36(1):41-48
2. Geraghty JG, Coveney EC, Sherry F, O'Higgins NJ, Duffy MJ. CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer. 1992;70(12):2831-2834
3. Kallioniemi OP, Oksa H, Aaran RK, Hietanen T, Lehtinen M, Koivula T. Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer. 1988;58(2):213-215
4. Lin DC, Genzen JR. Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing. Breast Cancer Research and Treatment. 2018;167:269-276
Method Name
Electrochemiluminescence Immunoassay (ECLIA)
Specimen Type
SerumSpecimen Required
Patient Preparation: For 12 hours before specimen collection, patient should not take multivitamins or dietary supplements (eg, hair, skin, and nail supplements) containing biotin (vitamin B7).
Supplies: Sarstedt 5 mL Aliquot Tube (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
0.75 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 7 days | |
| Frozen | 90 days |
Reference Values
Males: <30 U/mL (use not defined)
Females: <30 U/mL
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86300
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CA153 | Cancer Ag 15-3, (CA 15-3), S | 83083-6 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| CA153 | Cancer Ag 15-3, (CA 15-3), S | 83083-6 |
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.
mml-Neuroimmunology, mml-Neuro-oncology, mml-Pediatric